Randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of Lacticaseibacillus rhamnosus CRL1505 in the prevention of upper respiratory tract infections in a healthy pediatric population

Abstract

Randomized, double-blind, placebo-controlled, parallel-group, clinical trial to assess the efficacy of the intake of a probiotic product composed of Lacticaseibacillus rhamnosus CRL1505 strain in reducing or preventing upper respiratory tract infections (URTIs) in a healthy pediatric population.